Jianke and Beijing Tong Ren Tang Group Forge Strategic Partnership to Pioneer an Integrated 'Medical + Pharmaceutical' Internet Healthcare Model
VCBeat (WeChat ID: vcbeat) has learned that Beijing Tongrentang Co., Ltd. (Group) recently convened a symposium for distributors, attended by more than 100 distributors from across China. As a representative of internet pharmaceutical e-commerce and mobile healthcare enterprises, Jianke was invited to participate in the meeting. Xie Fangmin, CEO of Jianke, and Li Youchun, General Manager of its Wuhan branch, attended the event. Leveraging this opportunity, Jianke forged a strategic partnership with Tongrentang Co., Ltd. (Group) to integrate relevant resources and establish a closed-loop “medical + pharmaceutical” service model. This model encompasses the entire patient journey, including medical consultation, issuance of electronic prescriptions, medication selection and ordering, delivery and pickup, and chronic disease management.
Pictured: Xie Fangmin, CEO of Jianke, delivering the keynote address on stage
On the day of the event, Xie Fangmin, CEO of Jianke, delivered a keynote speech titled “How Pharmaceutical E-commerce and Internet Hospitals Drive the Sales of Traditional Chinese Medicine Patent Drugs.” At the venue, Mr. Xie also held in-depth discussions with key executives from Tongrentang Co., Ltd., including General Manager Di Shubing, Deputy General Manager Wang Qingquan, and Chief Advisor Zhang Runhong.
It is reported that Beijing Tongrentang Co., Ltd. (Group) will supply Jianke with 188 specifications of proprietary Chinese medicines, ensuring direct manufacturer supply and a 100% authenticity guarantee for high-quality pharmaceutical products, thereby jointly building a healthy value chain for the online sales platform. This means that patients can purchase relevant Tongrentang products without leaving home by logging into the Jianke Online Pharmacy APP or official website. Jianke will provide ample inventory, a superior logistics experience, and after-sales service.
Meanwhile, doctors affiliated with the Jianke Internet Hospital can also recommend appropriate Tongrentang pharmaceutical products to patients online and issue medication orders. After patients place their orders, Jianke handles unified delivery and follow-up services based on the order information.
Photo of the Beijing Tongrentang Co., Ltd. (Group) Distributor Symposium
Notably, Jianke will leverage its chronic disease management service team—the earliest established, largest-scale, and most professionally renowned in the industry—to provide professional chronic disease management services to Beijing Tongrentang Co., Ltd. (Group). It is reported that Jianke will launch themed campaigns focused on specific disease treatments for Tongrentang, share patient persona data with Tongrentang, and, leveraging Jianke’s leading internet technologies, deliver tailored service packages to different patient groups across various scenarios, thereby enhancing patients’ experience in seeking medical care and purchasing medications.
Xie Fangmin, CEO of Jianke, stated that the partnership with Beijing Tongrentang Co., Ltd. holds significant strategic importance for Jianke. Currently, Jianke is launching a health management service platform model driven by the dual engines of “medical care + pharmaceuticals,” completing the conceptual shift from disease-oriented to health-oriented approaches, and integrating all key segments of the internet healthcare closed loop, including patients, doctors, hospitals, pharmaceutical companies, and pharmacies.
As a century-old traditional Chinese medicine enterprise, Beijing Tongrentang Co., Ltd. (Group) possesses abundant resources in branding and distribution channels. The partnership with this company marks a significant step for Jianke in advancing from mobile healthcare to smart health. Whether through online medical consultations and medication purchases or offline prescription pickups, it enables the provision of more comprehensive and professional healthcare solutions for patients.
Having developed for over a decade, Jianke has been deeply engaged in the internet pharmaceutical industry and is one of the few companies in China to hold all three licenses (A, B, and C) for pharmaceutical e-commerce. Based on multiple indices from WeChat, Baidu, and Alexa, Jianke focuses on the B2C sector and ranks at the top of the industry in brand awareness, user base, and online traffic, demonstrating its strong presence in China’s internet healthcare landscape.
An efficient and professional chronic disease management system, an integrated online-offline user service framework, and rapidly expanding sales scale have established a complete smart healthcare closed loop. By centering on internet hospital services for chronic disease management, electronic prescription circulation systems, and direct supply of new and specialty drugs, Jianke has built a moat for its future high-speed growth. Leveraging advanced technology and innovation capabilities, Jianke has also implemented a strategic layout that connects the entire “healthcare + pharmaceuticals” value chain.